More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Encouraged by governmental and regulatory initiatives and the need to combat antibiotic-resistant bacteria, the large pharmaceutical companies and specialty players target antibiotic innovation. President Obama's announcement last week to develop...
DCAT Value Chain Insights

Partnering is a vital vehicle to drive innovation and eventual commercialization. So what are some of the most promising deals thus far in 2014? One important measure of pharmaceutical industry activity is the level of partnering activity among...
DCAT Value Chain Insights

Merck & Co.'s approval from the US Food and Drug Administration (FDA) of Keytruda (pembrolizumab), a drug to treat melanoma, is a key development not only for Merck, but for the industry as other companies seek to advance immunotherapies in the...
DCAT Value Chain Insights

BIO, PhRMA, GPhA, EGA as well as Pfizer, Sanofi, Novartis, Genentech, AbbVie, Boehringer Ingelheim, and Novo Nordisk offer input on the FDA's draft guidance on the clinical studies and related analytical testing needed to support biosimilarity....